

**Supplementary Table 1. HIV-1-specific CD8<sup>+</sup> T-cell responses in acute and early infection, the epitopes targeted and restricting MHC class I alleles.**

HLA	Protein	Epitope code	Clade-C Sequence	Corresponding OLP	HLA	Protein	Epitope code	Clade-C Sequence	Corresponding OLP
A2	p17	SL9	SLYNTVATL	#11, #12	A3002	p17	RY11	RSLYNTVATLY	#11, #12
A2	RT	AM9	ALTAICEEM	#170	A3002	RT	AY11	AQNPEIVIYQY	#190
A2	RT	VL9	VIYQYMDQL	#190	A3002	RT	KIY9	KLNWASQIY	#201, #202
A2	RT	IV9	ILKEPVHGV	#207	A3002	Int	KIY9	KIQNFRVYY	#269, #270
A2	gp41	SV10	SLLDTIAAV	#396	A3002	gp41	RY9	RIGPGQTFY	#330
A2	Nef	PL10	PLTGFWCFLK	#85	A3002	p17	SW11	SILRGGKDKW	#1
A2	Nef	VL10	VLQWKFDSQL	#91	A3002	p17	RL9	RFALNPGLL	#6, #7
A2	Vpr	AL9	ALIRILQQL	#285	A3002	p24	KV10	KNWMTDTLLV	#43
A2	Nef	GL9	GAFDLSFFL	#78	A3002	p17	AF8	ASRELERF	#6
A2	p24	IA9	ILRALGPGA	#45	A3002	RT	RY10	RAQNPEIVIY	#190
A2	p24	GA9	GVGGPSHKA	#48	A66	RT	ER11	ETFYVDGAANR	#224
A2	Rev	QL9	QAVRIIKIL	#96	A6801	p24	DA8	DTINEEAA	#28
A2	P15	QW9	QANFLGKIW	#58	A6801	Vif	ER10	EVHIPLGEAR	#408
A2	RT	QV8	QIYPGIKV	#202	A6802	Int	EL9	ETAYFILKL	#253
A2	Pol	QL9	QVRDQAEHL	#262	A6802	Int	EA10	ETAYFILKLA	#253
A2	RT	LI10	LVGPTPVNII	#162	A6802	RT	EA9	ETFYVDGAA	#223, #224
A0205	Pol	YI9	YTAFTIPSI	#183	B7/42/81	p24	SV9	SPRTLNAWV	#20
A3	p17	KK9	KIRLRPGGK	#2, #3	B7/42/81	p24	TL9	TPQDLNML	#25
A3	p17	RH9	RLRPGGKKH	#3	B7/42/81	p24	HA9	HPVHAGPIA	#29, #30
A3	p17	RLY10	RLRPGGKKHY	#3	B7/42/81	p24	GL9	GPSHKARVL	#48
A3	RT	AM9	ALTAICEEM	#170	B7/42/81	Nef	FL9	FPVRPQVPL	#76
A3	RT	GK9	GIPHCPAGLK	#178	B7/42/81	Nef	RM9	RPQVPLRPM	#76
A3	RT	KK11	KMRTAHTNDVK	#213	B7/42/81	Nef	RGF9	RPMTFKGAF	#77
A3	Vif	KK11	KIKPPLPSVRK	#422	B7/42/81	Nef	TL10	TPGPGVRYPL	#84
A3	gp120	TK10	TVYYGVPVW	#293, #294	B7/42/81	RT	SM9	SPAIFQSSM	#187
A3	gp41	RR11	RLRDILIIAR	#391	B7/42/81	vpr	FL9	FPRPWLHGL	#281, #282
A3	RT	KLK9	KLAGRWPVK	#254	B7/42/81	gp120	RI10	RPNNNTRKSI	#328
A11	RT	IN8	IYQEPFKN	#212	B7/42/81	Int	LI9	LPPIVAKEI	#244
A23/24	p17	HW9	HYMLKHLVV	#4	B7/42/81	Pro	TL11	TPVNIIGRNML	#163
A23/24	Nef	RW8	RYPLTFGW	#84	B7/42/81	RT	YL9	YPGIKVKQL	#202, #203
A23/24	RT	IL9	IYQEPFKNL	#211, #212	B7/42/81	Rev	RL10	RPAEPVPLQL	#102
A23/24	gp120	VW8	YYGVPVW	#293, #294	B7/42/81	p17	RLY10	RLRPGGKKHY	#3
A23/24	gp120	LY10	LFCASDAKAY	#295	B7/42/81	RT	SL10	SPINETPVVKL	#166
A23/24	gp41	RL9	RYLKDDQQLL	#366	B7/42/81	RT	RQL11	RPPLVKLWYQL	#221
A23/24	gp120	NL10	NYTNNTIYRLL	#373	B7/42/81	Vif	KL9	KPKKIKPPL	#422
A26	p24	EL9	EVIPMFTAL	#23	B7/42/81	RT	TL11	TPGIRYQYNVL	#184
A29	Nef	YY8	YFPDWQNY	#82, #83	B7/42/81	RT	GL9	GPKVKQWPPL	#168
A29	p17	RY11	RSLYNTVATLY	#11, #12	B8	p17	EV9	ELRSLYNTV	#11
A29	gp160	SY9	SFDPIP HY	#316	B8	p24	DI8	DIYKRVII	#36
A29	gp120	SY10	SFNCRGEFFY	#338	B8	Nef	WM8	WPAIRERM	#68
A29	gp120	FY9	FNCRGEFFY	#338	B8	RT	GL9	GPKVKQWPPL	#168
A29	p17	LY9	LYNTVATLY	#11	B8	gp41	YL8	YLKDQQQLL	#366
A30	Nef	YY8	YFPDWQNY	#82, #83	B8	P15	EL8	EPKDREPL	#64
A3002	p17	RLY10	RLRPGGKKHY	#3	B8	RT	VI8	VPRRKAKI	#274, #275

Supplementary  
Table 1.  
continued

HLA	Protein	Epitope code	Clade-C Sequence	Corresponding OLP
B14	p24	DA9	DRFFKTLRA	#41
B14	p15	CC9	CRAPRKKGC	#55
B14	gp41	EL9	ERYLKDQQL	#366
B1503	Tat	FY10	FQTKGGLGISY	#115
B1503	RT	FY10	FKRKGGIGGY	#265
B1503	p24	VF9	VVKVIEEKAF	#21
B1503	RT	IY9	IQQEFGIPY	#258, #259
B1503	RT	RY9	RKAKIICKDY	#275
B1503	RT	GL9	GKKAIGTVL	#162
B1510	p17	RL9	RFALNPGLL	#6, #7
B1510	p24	VL10	VHQQAISPRTL	#20
B1510	p24	GL9	GHQAAMQML	#26, #27
B1510	Vif	WI9	WHLGHGVSI	#411
B1510	p17	GI9	GKVSQNYPI	#18
B1510	Rev	IL9	IHSISERIL	#100
B1510	RT	TIL9	THLEGKIIIL	#249
B1510	Rev	GL11	GRPAEPVPLQL	#102
B1510	p17	KL8	KHYMLKHL	#4
B18	Nef	YF9	YPLTFGWCF	#84, #85
B18	Vif	LY10	LADQLIHMHY	#415
B18	RT	NY10	NETPGIRYQY	#184
B18	Int	VL9	VASCDKCQL	#246
B18	RT	NY9	NPEIVIYQY	#190
B18	RT	SY11	SEVNIVTDSQY	#230
B18	Rev	DI10	DEALLQAVRI	#95
B18	Vif	IY8	IEWRLRYY	#413
B18	Nef	QY9	QEILDLWVY	#81
B18	VPR	NL10	NEWTELLEEL	#279
B18	VPR	GW10	GPQREPYNNEW	#279
B35	Nef	VF8	VPLRPMTF	#76, #77
B35	RT	VY10	VPLDEDFRKY	#182
B35	RT	NQY9	NPEIVIYQY	#190
B35	gp120	DL9	DPPNPQEMVL	#299
B35	Tat	EW10	EPVDPNLEPW	#111
B35	Nef	YF9	YPLTFGWCF	#84, #85
B39	RT	IL9	IVTDSQYAL	#231
B44	Vif	SL9	SEGATPQDL	#24
B44	p24	RL11	RDYVDRFFKTL	#40
B44	p24	AW11	AEQATQDVKNW	#42
B44	Nef	GV11	GEVGFPVRPQV	#75
B45	RT	AA9	AETFYVDGGA	#223, #224
B45	p24	II10	IEEKAFSPEVI	#22

HLA	Protein	Epitope code	Clade-C Sequence	Corresponding OLP
B44	RT	SY11	SEVNIVTDSQY	#230
B44	RT	IW11	IEELREHLLKW	#194
B44	Int	QW11	QEEHEKYHSNW	#242
B53	p17	WF9	WASRELRF	#5
B53	p24	QW9	QATQDVKNW	#42
B53	Nef	YF9	YPLTFGWCF	#84, #85
B53	RT	EW10	EPVDPNLEPW	#111
B53	RT	QW11	QPIQLPEKDSW	#199
B57	p17	WF9	WASRELRF	#5
B57	p24	ISW9	ISPRTLNAW	#20
B57	p24	KF11	KAFSPEVIPMF	#22
B57	p24	TW10	TSTLQEIQIAW	#33, #34
B57	p24	QW9	QATQDVKNW	#42
B57	Nef	HW9	HTQGYFPDW	#82
B57	RT	IAW9	IAMESIVIW	#216
B57	Vif	VF9	VSRRANGWF	#405
B57	RT	AF10	QATWIPEWEF	#220
B57	RT	FF9	FSVPLDED	#181
B57	RT	EY9	ETKIGKAGY	#226
B57	RT	KI13	KAGYVTDRGRQKI	#226
B57	Pol	VI9	VTDRGRQKI	#226
Cw0202	RT	IY10	ILKEPVHGVY	#207
Cw0202	Pol	EY11	EILKEPVHGVY	#207
Cw3	p24	YL9	YVDRFFKTL	#40
Cw4	p24	QW9	QATQDVKNW	#42
Cw4	Nef	YY8	YFPDWQNY	#82, #83
Cw4	gp41	EW11	EIWDNMTWMQV	#371
Cw4	RT	TF10	TVLDVDAYF	#180
Cw6	gp120	II13	IRSENLTNNAKTI	#325
Cw6	gp120	LL12	LTNNAKTIIVHL	#325
Cw06	gp120	AL8	AKTIIVHL	#325
CW0602	Pol	KR9	KTGKYAKMR	#213
Cw7	Nef	KY11	KRQEILDLWVY	#81
Cw8	p24	TL9	TPQDLNTML	#25
Cw8	Rev	PL9	PAEPVPLQL	#102, #103
Cw8	RT	IL9	IVTDSQYAL	#231
Cw12	RT	IL9	IVTDSQYAL	#231
Cw1701	Rev	RL10	RPAEPVPLQL	#102
Cw18	p24	FFF9	FRDYVDRFF	#40
Cw18	p24	VI9	VRMYSVPVI	#37
Cw1801	RT	VL8	VRDQAEHL	#262

Supplementary Table 2. T-cell responses to OLPs that are not known to contain defined CD8+ T-cell epitopes.

PID	OLP #	Region	Sequence	No. of time-points where response was detected	No. of SFC/ $10^6$ PBMC
AS2-1037	#9	p17	EGCKQIMKQLQPALQTGT	1	260
AS5-0643	#52	p15	QRSNFKGPKRIVKCF	1	200
AS1-0703	#117	Tat	GRKKRRQRRSAPPSSEDH	2	4000; 520
AS3-0458	#125	Vpu	LIVALIIIAIVVWVTIAYIEY	1	240
AS2-0110	#229	RT	VSLTETTNQKTELQAIQL	2	360
AS2-0050	#229	RT	QKTELQAIQLALQDSGSEV	5	4000; 1500
AS3-0458	#252	INT	GYIEAEVIPAETGQETAY	1	180
AS3-0268	#287	Vpr	HFRIGCQHSRIGILRQRR	1	280

**Supplementary Table 3. HIV-1-specific T-cell responses determined by the ex vivo ELISPOT assay during the entire follow up period and responses measured using cultured ELISPOT assay at 52 weeks.**

Participant ID	Pre-culture		Post-culture	
	Responses detected from 4 to 26 weeks	Responses detected at 52 weeks	All responses detected at 52 weeks	Gag specific responses at 52 weeks
AS1-0703	10	3	4	0
AS1-0876	9	4	3	2
AS1-0919	16	4	9	0
AS2-0341	6	0	4	0
AS2-0358	20	5	0	0
AS2-0945	13	7	2	1
AS3-0740	12	3	3	3
AS5-0953	10	3	2	2
<b>TOTAL</b>	<b>96</b>	<b>29</b>	<b>27</b>	<b>8</b>